Resistance to keratolysis boosted by crosslinking

Article

Optimal resistance to in vitro keratolysis by collagenase A can be achieved by collagen crosslinking the deepithelialized anterior corneal surface for 30 minutes, according to a recently published study.

Optimal resistance to in vitro keratolysis by collagenase A can be achieved by collagen crosslinking the deepithelialized anterior corneal surface for 30 minutes, according to a study published in Cornea.

In a basic investigation, Barron artificial anterior chambers were used to perform ex vivo crosslinking of human corneas. The deepithelialized corneas were pretreated with riboflavin solution and irradiated with ultraviolet A (UVA) light for various durations. The corneas were then trephined and incubated with 0.3% collagenase A solution at 37 °C.

It was found that deepithelialized corneas that received no UV light and no riboflavin dissolved in 5.8 ± 0.6 hours. Increased resistance to dissolution was found in the crosslinked corneas, which demonstrated a time to dissolution of 17.8 ± 2.6 hours.

Longer UVA exposure increased the corneal tissues' resistance to collagenase, reaching a plateau at 30 minutes. Crosslinking the anterior corneas only provided the same amount of resistance as crosslinking both the anterior and posterior corneas.

Corneas that had been gamma-irradiated did not benefit from further crosslinking. They dissolved in 5.6 ± 1.2 hours when further crosslinked and 6.1 ± 0.6 hours when not.

To view an abstract of the study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.